Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00336466
Other study ID # 17747
Secondary ID
Status Completed
Phase Phase 2
First received June 12, 2006
Last updated November 26, 2007
Start date September 2004
Est. completion date May 2005

Study information

Verified date November 2007
Source University of Calgary
Contact n/a
Is FDA regulated No
Health authority Canada: Health Canada
Study type Interventional

Clinical Trial Summary

Context: Neurocognitive dysfunction complicates coronary artery bypass graft surgery. Neurocognitive dysfunction is a measurable problem with thinking. Erythropoietin may be a neuroprotectant.

Objective: To investigate the feasibility and safety of three doses of human recombinant erythropoietin to reduce neurocognitive dysfunction in coronary artery bypass graft patients.


Description:

Coronary artery bypass surgery (CABG) is performed each year on over 500,000 patients in the US and almost 30,000 patients in Canada to treat coronary artery disease. However, it is complicated by a significant postoperative risk of neurologic sequelae, including stroke and neurocognitive dysfunction (NCD). Clinically overt stroke, which may be seen in 1-4% of patients, is far less common than NCD, which is reported in approximately 50-75% of patients at discharge, 20-50% at 6 weeks and up to 40% at five years.Human recombinant erythropoietin (rh-Epo) is not only approved in this population for prophylactic use to reduce blood transfusions, but has become an agent of intense interest for neuroprotection as a result of in vitro data, animal experiments, and now, two promising preliminary trials in human patients. There are not, however, any pilot data by which to estimate an appropriate dose or treatment effect of rh-Epo on NCD specifically. It is imperative both to refine estimates of control group incidence rates, treatment effect and test variability in CABG, as well to demonstrate the feasibility and safety of a study protocol, prior to embarking on a larger randomized controlled trial powered with an adequate sample size to investigate the efficacy of rh-Epo in the reduction of peri-operative NCD. We propose a six month prospective study in CABG patients to investigate the feasibility and safety of three prophylactic doses of human recombinant erythropoietin (rh-Epo) in a randomized, placebo controlled study. The four study arms are: placebo, 375 U/kg, 750 U/kg, or 1500 U/kg of human recombinant erythropoietin intravenously divided in three doses, the day before, the day of and the day after surgery. The primary outcomes of this pilot will be study feasibility and patient safety as measured by ICU and Hospital length of stay, 28 day all cause mortality, and incidence of morbidity including pure red cell aplasia (PRCA), stroke, myocardial infarction, re-operation, deep vein thrombosis, and pulmonary thromboembolism. The secondary outcome will be the incidence of neurocognitive dysfunction among the four study arms and between placebo and rh-Epo at any dose. As well, little is known about the pharmacology of rh-Epo in crossing the blood-brain barrier. In those patients receiving a spinal anesthetic in addition to a general anesthetic as part of their normal care, CSF will be analyzed for rh-Epo concentration, and then compared to drug dose and serum level.


Recruitment information / eligibility

Status Completed
Enrollment 32
Est. completion date May 2005
Est. primary completion date
Accepts healthy volunteers No
Gender Both
Age group 45 Years to 75 Years
Eligibility Inclusion Criteria:

- First time cardiac surgical patients

- Elective or urgent on pump coronary artery bypass grafting (CABG)

- Age 45-75

- Signed, informed consent

Exclusion Criteria:

- Emergent CABG less than 48 hours from presentation

- Symptomatic cerebrovascular disease

- Atrial fibrillation

- Congestive Heart Failure within 2 weeks of surgery

- Malignancy or pre-malignant state within 5 years

- Significant Kidney disease (creatinine >150 umol/L)

- Significant Liver disease (Bilirubin > 20 umol/L)

- Significant Lung Disease (FEV1< 1.5 L, pO2 <70 on room air, pCO2 >45)

- Psychiatric Illness requiring medication

- Alcohol Abuse

- Less than Grade 7 education or inability to read

- Allergy to Eprex, past history of pure red cell aplasia

- Anemia or untreated iron deficiency

- Pregnancy

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
Human recombinant erythropoietin


Locations

Country Name City State
Canada Foothills Hospital Calgary Alberta

Sponsors (3)

Lead Sponsor Collaborator
University of Calgary Calgary Health Region, Ortho Biotech, Inc.

Country where clinical trial is conducted

Canada, 

Outcome

Type Measure Description Time frame Safety issue
Primary Safety
Primary Feasibility
Secondary Incidence of Neurocognitive Dysfunction
See also
  Status Clinical Trial Phase
Recruiting NCT05054179 - Pecto-Intercostal Fascial Plane Block Catheter Trial for Reduction of Sternal Pain Phase 2/Phase 3
Completed NCT04051021 - Non-Pharmacological Interventions on Patient Experience and Healthcare Utilization in Adult Cardiac Surgery Patients N/A
Recruiting NCT04604886 - The Consistency of Cardiac Output Measured by Pulmonary Artery Catheter and LiDCO in Cardiac Surgical Patients N/A
Recruiting NCT04075981 - Prevention Atrial Fibrillation by BOTulinum Toxin Injections (BOTAF) Phase 3
Completed NCT04062396 - Comparison of Remowell 2 and Inspire on Delirium and Cognitive Dysfunction N/A
Recruiting NCT04709705 - DMSO Cryopreserved Platelets in Cardiopulmonary Bypass Surgery (CRYPTICS) Phase 2/Phase 3
Not yet recruiting NCT05563662 - SURgical Registry of ENDocarditis EuRope
Withdrawn NCT03289104 - Improving Sternal Healing After Cardiac Surgery: Sternal Wire vs ZIPFIX N/A
Completed NCT03563196 - Diagnosis Of Pulmonary Complications After Cardiac Surgery In Children
Completed NCT02964026 - Study of Clinical Outcomes Associated With the Pulmonary Artery Catheter (PAC) in Cardiac Surgery Patients N/A
Completed NCT04199039 - Effects of Endotracheal Tube Fixation Methods on Hemodynamic Parameters During Endotracheal Suction N/A
Completed NCT02471001 - The Levels of Anaesthetics in Heart Muscle During Heart Surgery N/A
Completed NCT02325726 - RRI Compared With NephroCheckTM to Predict Acute Renal Failure After Cardiac Surgery. N/A
Completed NCT01246947 - Tricuspid Annuloplasty for Moderate Tricuspid Regurgitation Associated With Miral Operation N/A
Completed NCT01151254 - Comparison of Propofol Based Versus Volatile Based Anesthesia and Postoperative Sedation N/A
Completed NCT00821262 - Sevoflurane in Cardiac Surgery Phase 4
Completed NCT00996099 - Continuous Glucose Monitoring Combined With Computer Algorithm for Intensive Insulin Therapy in Cardiosurgical Patients N/A
Completed NCT00617955 - Effects of Aprotinin During Cardiac Surgery/Long Term Death Rates N/A
Completed NCT00337805 - Double Blind Randomized Trial of Saline vs Pentaspan for Resuscitation After Cardiac Surgery Phase 2/Phase 3
Recruiting NCT04978636 - Low Tidal Volume Ventilation With Hyperoxia Avoidance During Cardiopulmonary Bypass (The FOCUS Trial) N/A